<DOC>
	<DOC>NCT02510599</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.</brief_summary>
	<brief_title>Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis</brief_title>
	<detailed_description>Patients will be administered solithromycin for 13 weeks with regular safety visits and liver biopsies at baseline and after treatment.</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Histologic evidence of NASH based on liver biopsy obtained within 180 days NAS&gt; or = 5 Able to swallow capsules intact Symptoms of acute liver disease Cirrhosis on liver biopsy Positive HIV or Hepatitis tests Primary Biliary Cirrhosis Poorly controlled diabetes with HgA1C &gt;8.5% ALT &gt;4fold upper limit of normal QTcF &gt;450 msec CrCl &lt;40 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NASH</keyword>
	<keyword>Liver disease</keyword>
</DOC>